Therapeutic Response
ER positive, ESR1 activating variants, and HER2-negative status confers therapeutic sensitivity to Camizestrant in combination with Ribociclib in patients with Invasive Breast Carcinoma.
Statements
| Source and description |
|---|
ER positive, ESR1 activating variants, and HER2-negative status confers therapeutic sensitivity to Camizestrant in combination with Ribociclib in patients with Invasive Breast Carcinoma.
| Source and description |
|---|